Extended use of TRZ is associated with the development of gastrointestinal adverse effects such as nausea, dyspepsia, vomiting, abdominal pain, diarrhea or constipation, and hypoglycemia
[16] While some participants in clinical studies have reported menstrual changes, these are generally attributed to the metabolic effects of weight loss rather than direct drug action on reproductive tissues, and are not classified as common adverse effects in the UK product information for GLP-1 medications
Protein is essential for muscle repair, growth, and maintenance
Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats
Collagens in the liver extracellular matrix bind hepatocyte growth factor